KALV — KalVista Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1348911 ·
Last close
$27.00
Market Cap
$1.44B
52W High
$27.00
52W Low
$15.09
ADV30
3,208,367
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 40,863,000 | 37,773,000 | -23,442,000 | -23,487,000 | 328,917,000 | 213,768,000 | 348,569,000 |
| Sep 2025 | 13,692,000 | 12,460,000 | -46,050,000 | -49,482,000 | 339,931,000 | 243,497,000 | 322,932,000 |
| Jul 2025 | 1,426,000 | 836,000 | -59,009,000 | -60,096,000 | 215,505,000 | 124,304,000 | 174,715,000 |
| Apr 2025 | 0 | — | -50,016,000 | -52,226,000 | 250,770,000 | 131,615,000 | 155,379,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-142,002,000
Investing CF
$25,549,000
Financing CF
$181,107,000
CapEx
$-1,282,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.39
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-786,181,000
Inventory
$4,002,000
Receivables
$17,327,000
ST Investments
$71,262,000
EBIT TTM
$-165,024,000
Pretax Income TTM
$-181,832,000
Interest Exp TTM
$16,808,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$114,480,000
EBITDA
$-138,447,008
Free Cash Flow
—
Enterprise Value
$1,436,785,920
Total Cash
$285,030,016
Total Debt
$284,312,000
Shares Out
53,240,888
Trailing EPS
$-3.94
Book Value
$-0.38
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | 335,375,000 | 338,086,000 | — | — |
| Apr 2025 | 0 | -182,981,000 | -183,444,000 | 250,770,000 | 155,379,000 | — | -152,907,000 |
| Apr 2024 | 0 | -131,993,000 | -126,644,000 | 235,404,000 | 28,822,000 | — | -89,231,000 |
| Apr 2023 | 0 | -95,086,000 | -92,907,000 | 183,202,000 | 22,177,000 | — | -75,261,000 |
| Apr 2022 | 0 | -81,310,000 | -82,339,000 | — | — | — | -78,134,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.71
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $27.00 · call volume: 524 · put volume: 365
Expected Move to 2026-12-18:
±$1.91
(7.07%) —
implied range
$25.09 –
$28.91
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARDX | ARDELYX, INC. | $1.44B | $5.84 | — |
| AVBP | ArriVent BioPharma, Inc. | $1.46B | $31.36 | — |
| MLTX | MoonLake Immunotherapeutics | $1.41B | $19.19 | — |
| PRGO | PERRIGO Co plc | $1.41B | $10.16 | — |
| GHRS | GH Research PLC | $1.49B | $21.70 | — |
News headlines (Yahoo Finance, 1h cache)
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
2026-06-11 12:41 · Yahoo
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
2026-06-04 16:00 · Yahoo
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
2026-05-31 16:08 · Yahoo
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
2026-05-28 11:00 · Yahoo
A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains
2026-05-10 00:24 · Yahoo
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
2026-04-30 11:50 · Yahoo
IBT portfolio manager says KalVista deal signals Biotech 2.0 growth
2026-04-30 09:09 · Yahoo
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
2026-04-29 22:07 · Yahoo
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
2026-04-29 20:03 · Yahoo
Sector Update: Health Care Stocks Fall Late Afternoon
2026-04-29 19:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.